Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
DeVita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73(6):881-895.
- Moore MR, Jones SE, Bull JM, et al. MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients. Cancer. 1973;32(1):52-60.
DeVita VT, Canellos GP, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet. 1975;1(7901):248-250.
Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4(9):1295-1306.
Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252-259.
- Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
- Tran E, Turcotte S, Gros A, et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science. 2014;344(6184):641-645.
Hanahan D, Weinberg RA. Hallmarks of Cancer. An organizing principle for cancer medicine. In DeVita VT, Jr, Lawrence TS, Rosenberg SA (eds). DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2014; chap 2:24-44.
Disclosure statements are available on the authors' profiles: